Focused on sustained investment and professional services in emerging industries in China and globally.
￥1.93B+
Subscribed Capital
25
Total Funds Managed
Investment Cases
News
Breaking | Karsgen Raises Nearly 500 Million RMB to Advance Nuclear Receptor and GPCR Innovative Drug R&D
Greatpower Nickel & Cobalt Partners with Anhui Technology to Launch Comprehensive New Energy Cooperation
National Honor! Sagebot Recognized as a 'National Intellectual Property Demonstration Enterprise Candidate'
Nearly 100 Million Yuan Raised! GP Nickel & Cobalt Successfully Completes Series F Financing
Another Milestone! Kangduo Robot® Thoracoabdominal Endoscopic Surgical System Receives EU CE Certification!
Exclusive! China Medical Robot Industry Report: Weimai Medical Leads the Vascular Interventional Robot Track with Technology
Great News! Two Products Receive CE Certification, Accelerating Global Expansion
Whalevein ETCath Interventional Surgical Robot Approved! The 'Eye-Hand-Brain' Trinity Reconstructs the Interventional Ecosystem!
HaiHe Biopharma's Highly Selective PI3Kα Inhibitor Risoertinib Goes Global - Official Application for NDA in Japan
Beijing Jinshui & Aqueti Strategic Cooperation: Driving AI Implementation in Smart Water Conservancy
Innovative Drug CS0159 Granted FDA Breakthrough Therapy Designation; Karsgen Reaches New Milestone in Globalization
Youlan International Successfully Lists on Nasdaq
Haihe Biopharma's Paclitaxel Oral Solution Filing for Breast Cancer Indication Officially Accepted
Greatpower Energy and Jinchuan International Sign Agreement to Jointly Develop Mineral Resources in Zambia
Great News! Haihe Biopharma's Paclitaxel Oral Solution Approved for Marketing
Dual Approval in China and the U.S.! Kethli Pharma's Class I New Drug CS060380 Receives IND Clearance
Magnicept Medical Receives First Domestic RDN Certificate! Netrod® Mesh Renal Artery Radiofrequency Ablation System Approved by NMPA
Kethli Pharma's Class I New Drug CS060304 Approved for Clinical Trials for New Indication (HoFH)
Haihe Biopharma’s Innovative Drug Gumarontinib (MET Inhibitor) Approved for Launch in Japan
CureGenix Receives China IND Approval for Class I New Drug CS060304
SyMap Medical Completes Series D Financing of Several Hundred Million Yuan, Led by CPE, Followed by Shanghai Biomedical Fund, Dingxin, and Xiaochi
Huiyun Shares Successfully Secures Investment from Taixing State-owned Assets Platform, Transitioning to State-owned Controlled Status
Zensun Sci-tech Successfully Completes Targeted Private Placement of Shares
LungHealth MedTech Completes Series C Financing of Over 100 Million RMB, Leading the Wave of Localization for Flexible Surgical Robots
ASR Microelectronics, Invested by Jiuyou Fund, Files for Registration on China's STAR Market
